246 related articles for article (PubMed ID: 9404706)
1. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
2. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic.
Jabali Y; Starý J; Hak J; Blazek B; Hrstkova H; Mihál V; Mydlil J; Timr P; Gajdos P
Med Pediatr Oncol; 2000 Nov; 35(5):493-5. PubMed ID: 11070483
[No Abstract] [Full Text] [Related]
4. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Kawasaki H; Isoyama K; Eguchi M; Hibi S; Kinukawa N; Kosaka Y; Oda T; Oda M; Nishimura S; Imaizumi M; Okamura T; Hongo T; Okawa H; Mizutani S; Hayashi Y; Tsukimoto I; Kamada N; Ishii E
Blood; 2001 Dec; 98(13):3589-94. PubMed ID: 11739161
[TBL] [Abstract][Full Text] [Related]
5. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).
Isoyama K; Eguchi M; Hibi S; Kinukawa N; Ohkawa H; Kawasaki H; Kosaka Y; Oda T; Oda M; Okamura T; Nishimura S; Hayashi Y; Mori T; Imaizumi M; Mizutani S; Tsukimoto I; Kamada N; Ishii E
Br J Haematol; 2002 Sep; 118(4):999-1010. PubMed ID: 12199778
[TBL] [Abstract][Full Text] [Related]
6. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
7. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.
Kosaka Y; Koh K; Kinukawa N; Wakazono Y; Isoyama K; Oda T; Hayashi Y; Ohta S; Moritake H; Oda M; Nagatoshi Y; Kigasawa H; Ishida Y; Ohara A; Hanada R; Sako M; Sato T; Mizutani S; Horibe K; Ishii E
Blood; 2004 Dec; 104(12):3527-34. PubMed ID: 15297313
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).
Hilden JM; Frestedt JL; Moore RO; Heerema NA; Arthur DC; Reaman GH; Kersey JH
Blood; 1995 Nov; 86(10):3876-82. PubMed ID: 7579356
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Gaiger A; Linnerth B; Mann G; Schmid D; Heinze G; Tisljar K; Haas OA; Gadner H; Lion T
Eur J Haematol; 1999 Aug; 63(2):86-93. PubMed ID: 10480287
[TBL] [Abstract][Full Text] [Related]
11. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
12. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.
Rubnitz JE; Shuster JJ; Land VJ; Link MP; Pullen DJ; Camitta BM; Pui CH; Downing JR; Behm FG
Blood; 1997 Feb; 89(4):1143-6. PubMed ID: 9028935
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
14. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
15. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification.
Maloney K; McGavran L; Murphy J; Odom L; Stork L; Wei Q; Hunger S
Leukemia; 1999 Nov; 13(11):1708-12. PubMed ID: 10557042
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J
Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205
[TBL] [Abstract][Full Text] [Related]
17. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Linker C; Damon L; Ries C; Navarro W
J Clin Oncol; 2002 May; 20(10):2464-71. PubMed ID: 12011123
[TBL] [Abstract][Full Text] [Related]
18. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
19. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
20. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]